Towards Drug Repurposing in Cancer Cachexia: Potential Targets and Candidates

As a multifactorial and multiorgan syndrome, cancer cachexia is associated with decreased tolerance to antitumor treatments and increased morbidity and mortality rates. The current approaches for the treatment of this syndrome are not always effective and well established. Drug repurposing or reposi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Joana M. O. Santos, Alexandra C. Costa, Tânia R. Dias, Setareh Satari, Maria Paula Costa e Silva, Rui M. Gil da Costa, Rui Medeiros
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	cancer cachexia drug repurposing drug repositioning Medicine R Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/f6d4ed0b4f014da6a9ec9e7f517439e8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f6d4ed0b4f014da6a9ec9e7f517439e8
record_format	dspace
spelling	oai:doaj.org-article:f6d4ed0b4f014da6a9ec9e7f517439e82021-11-25T18:39:13ZTowards Drug Repurposing in Cancer Cachexia: Potential Targets and Candidates10.3390/ph141110841424-8247https://doaj.org/article/f6d4ed0b4f014da6a9ec9e7f517439e82021-10-01T00:00:00Zhttps://www.mdpi.com/1424-8247/14/11/1084https://doaj.org/toc/1424-8247As a multifactorial and multiorgan syndrome, cancer cachexia is associated with decreased tolerance to antitumor treatments and increased morbidity and mortality rates. The current approaches for the treatment of this syndrome are not always effective and well established. Drug repurposing or repositioning consists of the investigation of pharmacological components that are already available or in clinical trials for certain diseases and explores if they can be used for new indications. Its advantages comparing to de novo drugs development are the reduced amount of time spent and costs. In this paper, we selected drugs already available or in clinical trials for non-cachexia indications and that are related to the pathways and molecular components involved in the different phenotypes of cancer cachexia syndrome. Thus, we introduce known drugs as possible candidates for drug repurposing in the treatment of cancer-induced cachexia.Joana M. O. SantosAlexandra C. CostaTânia R. DiasSetareh SatariMaria Paula Costa e SilvaRui M. Gil da CostaRui MedeirosMDPI AGarticlecancercachexiadrug repurposingdrug repositioningMedicineRPharmacy and materia medicaRS1-441ENPharmaceuticals, Vol 14, Iss 1084, p 1084 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cancer cachexia drug repurposing drug repositioning Medicine R Pharmacy and materia medica RS1-441
spellingShingle	cancer cachexia drug repurposing drug repositioning Medicine R Pharmacy and materia medica RS1-441 Joana M. O. Santos Alexandra C. Costa Tânia R. Dias Setareh Satari Maria Paula Costa e Silva Rui M. Gil da Costa Rui Medeiros Towards Drug Repurposing in Cancer Cachexia: Potential Targets and Candidates
description	As a multifactorial and multiorgan syndrome, cancer cachexia is associated with decreased tolerance to antitumor treatments and increased morbidity and mortality rates. The current approaches for the treatment of this syndrome are not always effective and well established. Drug repurposing or repositioning consists of the investigation of pharmacological components that are already available or in clinical trials for certain diseases and explores if they can be used for new indications. Its advantages comparing to de novo drugs development are the reduced amount of time spent and costs. In this paper, we selected drugs already available or in clinical trials for non-cachexia indications and that are related to the pathways and molecular components involved in the different phenotypes of cancer cachexia syndrome. Thus, we introduce known drugs as possible candidates for drug repurposing in the treatment of cancer-induced cachexia.
format	article
author	Joana M. O. Santos Alexandra C. Costa Tânia R. Dias Setareh Satari Maria Paula Costa e Silva Rui M. Gil da Costa Rui Medeiros
author_facet	Joana M. O. Santos Alexandra C. Costa Tânia R. Dias Setareh Satari Maria Paula Costa e Silva Rui M. Gil da Costa Rui Medeiros
author_sort	Joana M. O. Santos
title	Towards Drug Repurposing in Cancer Cachexia: Potential Targets and Candidates
title_short	Towards Drug Repurposing in Cancer Cachexia: Potential Targets and Candidates
title_full	Towards Drug Repurposing in Cancer Cachexia: Potential Targets and Candidates
title_fullStr	Towards Drug Repurposing in Cancer Cachexia: Potential Targets and Candidates
title_full_unstemmed	Towards Drug Repurposing in Cancer Cachexia: Potential Targets and Candidates
title_sort	towards drug repurposing in cancer cachexia: potential targets and candidates
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/f6d4ed0b4f014da6a9ec9e7f517439e8
work_keys_str_mv	AT joanamosantos towardsdrugrepurposingincancercachexiapotentialtargetsandcandidates AT alexandraccosta towardsdrugrepurposingincancercachexiapotentialtargetsandcandidates AT taniardias towardsdrugrepurposingincancercachexiapotentialtargetsandcandidates AT setarehsatari towardsdrugrepurposingincancercachexiapotentialtargetsandcandidates AT mariapaulacostaesilva towardsdrugrepurposingincancercachexiapotentialtargetsandcandidates AT ruimgildacosta towardsdrugrepurposingincancercachexiapotentialtargetsandcandidates AT ruimedeiros towardsdrugrepurposingincancercachexiapotentialtargetsandcandidates
_version_	1718410871538974720

Towards Drug Repurposing in Cancer Cachexia: Potential Targets and Candidates

Ejemplares similares